Fap Source Anti-tumor Ctl Epitope Peptide P265 And Application Thereof

  • Published: Aug 17, 2016
  • Earliest Priority: May 27 2016
  • Family: 2
  • Cited Works: 5
  • Cited by: 0
  • Cites: 4
  • Additional Info: Cited Works
Full-text?

The full document isn't yet available to us from the patent office.

Abstract

The invention belongs to the technical field of polypeptide in the biological chemistry filed and particularly relates to an FAP source anti-tumor CTL epitope peptide P265 and application thereof in preparation of tumor therapeutic peptide vaccine. The anti-tumor CTL epitope peptide P265 is nonapeptide, the molecular weight is 1,040.18, the specific sequence is FIIDTTYPA. More than 90% of specific antigen FAP which has high expression in epithelial ovarian tumor and almost no expression in normal tissue is used, HLA-A2 restrictive CTL epitope of the FAP is predicated and screened according to the primary structure of the FAP, it is determined that the CTL epitope peptide and the HLA-A2 molecules can produce high combining capacity, specificity CTL reaction can be effectively activated, and the FAP source anti-tumor CTL epitope peptide P265 has the feasibility of becoming the therapeutic tumor peptide vaccine.


Claims

Information currently unavailable.

Document Preview
No Image Yet
Document History
  • Publication: Aug 17, 2016
  • Application: May 27, 2016
    CN CN 201610361347 A
  • Priority: May 27, 2016
    CN CN 201610361347 A

Download Citation


Sign in to the Lens

Feedback